SS-31 at a Glance

• SS-31 is a synthetic aromatic-cationic tetrapeptide D-Arg-2′,6′-dimethylTyr-Lys-Phe-NH₂, developed in the Szeto–Schiller laboratories at Weill Cornell and later carried into clinical development as elamipretide also known by the code MTP-131 and the earlier trade name Bendavia.
• Its defining property is accumulation in the inner mitochondrial membrane independently of membrane potential where it associates with cardiolipin the signature phospholipid on which cristae architecture and respiratory-chain organisation depend.
• The mechanistic account has shifted over two decades from “mitochondria-targeted antioxidant” to cardiolipin-protective and membrane-electrostatic a distinction that changes which controls a study needs.
• Preclinical cardiac and pulmonary data are extensive: reduced infarct size in ischaemia-reperfusion models, normalised mitochondrial dynamics in canine heart failure, attenuated pulmonary arterial hypertension and acute lung injury in rodents.
• Human results are genuinely mixed. Randomised trials in ST-elevation myocardial infarction, heart failure with reduced ejection fraction and primary mitochondrial myopathy all missed their primary endpoints. Open-label work in Barth syndrome reported large functional gains, and on that basis elamipretide received FDA accelerated approval in September 2025 for that one ultra-rare indication.
• That approval covers one prescription product for one disease. Material sold to laboratories as SS-31 is not that product and is research-use-only.

What Is SS-31?

SS-31 is a four-residue synthetic peptide with the sequence D-Arg-Dmt-Lys-Phe-NH₂ where Dmt is 2′,6′-dimethyltyrosine and the C-terminus is amidated. The hydrochloride salt developed clinically as elamipretide is catalogued in PubChem as CID 11764719, with molecular formula C₃₂H₄₉N₉O₅ and a molecular weight of approximately 640 Da.

Three structural features do the work. The D-arginine at position 1 resists aminopeptidase cleavage, which is why a peptide this short survives in plasma at all. The dimethyltyrosine supplies an electron-rich aromatic ring. And arginine plus lysine gives the molecule a net charge of 3+ across an unusually small, partly aromatic frame.

That charge-to-aromaticity ratio is the origin of the compound’s most-cited property. Conventional mitochondria-targeted molecules such as the triphenylphosphonium conjugates accumulate in the matrix because they are lipophilic cations driven by the inner-membrane potential. SS-31 does not behave that way. It concentrates in the inner membrane itself, and it does so in de-energised mitochondria as well as polarised ones, which means uptake cannot be explained by potential-driven partitioning. The consequence is practical rather than merely mechanistic: a compound whose accumulation is potential-independent still reaches the ischaemic, depolarised mitochondria that are the whole point of studying it.

The Szeto–Schiller series began as an effort to design cell-permeable opioid-peptide analogues and produced, more or less serendipitously, a set of molecules that concentrated in mitochondria. SS-31 advanced furthest and remains the reference compound for the aromatic-cationic class.

How Does SS-31 Work?

Cardiolipin Binding in the Inner Mitochondrial Membrane

Cardiolipin is a dimeric phospholipid with four acyl chains and a small headgroup, found almost exclusively in the inner mitochondrial membrane, where it constitutes roughly 15–20% of phospholipid content. Its conical geometry favours the negative curvature that forms cristae, and it forms specific complexes with respiratory-chain components including cytochrome c oxidase, the ADP/ATP carrier and cytochrome c itself.

Birk and colleagues (2013, PMID 23813215) reported that SS-31 interacts with cardiolipin and, in doing so, re-energises ischaemic mitochondria. The companion argument from the same group is that cardiolipin oxidation converts cytochrome c from an electron carrier into a peroxidase: bound to peroxidised cardiolipin, it loses its electron-shuttling function and gains a destructive one. Protecting the cardiolipin–cytochrome c interaction therefore preserves electron flux and simultaneously removes a source of further oxidation.

Szeto’s 2014 framing (PMID 24117165) described SS-31 as a first-in-class cardiolipin-protective compound rather than an antioxidant, and that reframing is the single most useful thing to grasp about the literature. The antioxidant description came first historically and persists in secondary sources, but it does not survive contact with the mechanistic data.

Membrane Surface Electrostatics

The most rigorous mechanistic work takes a further step away from chemistry and toward physics. Allen and colleagues (2020, PMID 32273339) reported that SS-31 binds lipid bilayers and modulates surface electrostatics as a key component of its mechanism, with the effect scaling with anionic lipid content rather than depending on a discrete binding pocket.

A 3+ cation adsorbing to an anionic membrane surface neutralises local negative charge and alters the surface potential experienced by every peripheral membrane protein nearby. That is a diffuse, non-saturable, physicochemical mode of action, and it explains why SS-31 produces broad effects on inner-membrane biology without a nameable receptor. It also predicts something awkward: any sufficiently cationic amphipathic peptide should do some of this. Structure-activity work across the tetrapeptide series finds activity does track with cationic and aromatic character, though not uniformly across assays.

Cristae Architecture and Respiratory-Chain Organisation

Because cardiolipin organises curvature and anchors respiratory complexes, a cardiolipin-directed compound is expected to act on cristae morphology and on the assembly state of the electron transport chain. Chavez and colleagues (2020, PMC7334473) mapped the mitochondrial protein interaction landscape of SS-31 using chemical cross-linking mass spectrometry and reported altered interactions among inner-membrane proteins, including components involved in ATP synthesis and cristae organisation, rather than a single high-affinity target. In the Sabbah group’s canine heart-failure work, long-term elamipretide therapy was associated with normalisation of abnormal mitochondrial dynamics, fission-fusion balance, mitochondrial number and size distribution, the organelle-level readout of the same idea.

Reactive Oxygen Species as a Downstream Consequence

Reduced mitochondrial ROS production is among the most consistently reported effects of SS-31 across models, and it is the observation that generated the original antioxidant label. The mechanistic reading now runs the other way. A respiratory chain with intact cardiolipin, properly seated complexes and cytochrome c doing its electron-carrier job leaks fewer electrons to molecular oxygen, so lower ROS is a consequence of restored electron transport efficiency rather than the primary event. That distinction predicts SS-31 should be ineffective where mitochondrial ROS arises by a route unrelated to cardiolipin or complex organisation.

Research Evidence

Isolated Mitochondria and Cell Systems

The founding observation is over twenty years old. Zhao and colleagues (2004, PMID 15178689) reported that cell-permeable peptide antioxidants targeted to the inner mitochondrial membrane inhibited mitochondrial swelling, oxidative cell death and reperfusion injury, the paper that established the series as a pharmacological class. In vitro concentrations across this literature are typically reported in the nanomolar to low-micromolar range. One methodological caution recurs: because the compound partitions into membranes, the meaningful variable is peptide-to-lipid ratio rather than bulk concentration, and studies reporting only the latter are hard to compare.

Cardiac Ischaemia-Reperfusion Models

This is the deepest body of preclinical work and the reason the compound matters to cardiothoracic research. The canonical finding is a reduction in infarct size when the peptide is administered before or at the moment of reperfusion, reported across rodent and large-animal models along with preserved mitochondrial respiratory function in reperfused myocardium.

The mechanistic logic fits the pathophysiology closely. Reperfusion injury is driven by a ROS burst at the moment oxygen returns, by calcium overload, and by opening of the mitochondrial permeability transition pore, and cardiolipin oxidation sits upstream of all three. A cardiolipin-protective compound that reaches depolarised mitochondria is, on paper, almost ideally placed.

Doses are reported in conventional preclinical terms: intravenous or intraperitoneal administration of roughly 1–3 mg/kg in rodents, often as an infusion begun shortly before reperfusion, with lower per-kilogram rates in large-animal work. These figures appear here strictly as the cited animal studies report them. They are not dose recommendations and do not translate to any other species, route or context.

Heart Failure Models

Beyond acute ischaemia, the Sabbah group examined chronic administration in dogs with experimentally induced advanced heart failure and reported improvement in left ventricular and mitochondrial function, normalisation of mitochondrial dynamics, and effects extending to skeletal muscle. That last finding matters because exercise intolerance in heart failure is only partly cardiac.

Pulmonary Models

For a thoracic readership the lung literature deserves equal weight; it is smaller but consistent in direction. In mice subjected to transverse aortic constriction, SS-31 attenuated the resulting pulmonary arterial hypertension (PMID 27063219), a model in which pulmonary vascular remodelling is secondary to left-heart pressure loading, making it a useful bridge between the cardiac and pulmonary literatures.

In neonatal mice modelling acute respiratory distress syndrome, SS-31 was reported to ease acute lung injury with effects attributed to TXNIP expression and NLRP3 inflammasome activation, placing the compound upstream of a redox-sensitive sterile-inflammation pathway. Separate work has examined SS-31 in bleomycin-induced pulmonary fibrosis in mice. These are individually modest studies from different groups pointing the same way: suggestive, not definitive.

Human Clinical Trials, What They Actually Returned

This is where the literature becomes genuinely instructive, and where most secondary coverage of SS-31 is misleading by omission.

Acute myocardial infarction. The EMBRACE STEMI trial tested intravenous MTP-131 during primary percutaneous coronary intervention in first anterior STEMI. The primary endpoint, creatine kinase-MB area under the curve over 72 hours, showed no benefit: 5,785 ± 426 ng·h/mL on placebo against 5,570 ± 486 ng·h/mL on MTP-131, not significant (PMID 26586786). The peptide was safe and well tolerated. It did not reduce infarct size.

Heart failure with reduced ejection fraction. The PROGRESS-HF phase 2 trial randomised 71 patients to placebo, 4 mg or 40 mg daily for 28 days. No significant differences in change in left ventricular end-systolic volume or ejection fraction were observed between placebo and either active arm (PMID 32068002).

Primary mitochondrial myopathy. An early dose-escalation study and a randomised crossover trial produced encouraging signals. The definitive phase 3 MMPOWER-3 trial then failed: elamipretide did not improve the six-minute walk test or fatigue relative to placebo (PMID 37268435). A later post hoc analysis examined genotype-specific subgroups, which is hypothesis-generating rather than confirmatory.

Barth syndrome. Barth syndrome is caused by TAZ mutations that disrupt cardiolipin remodelling, producing elevated monolysocardiolipin relative to mature cardiolipin. It is the one disease where a cardiolipin-directed compound has an exact mechanistic rationale. TAZPOWER randomised 12 subjects to 40 mg/day elamipretide or placebo in a 12-week crossover design; neither primary endpoint was met in that randomised phase. In the open-label extension, eight subjects reaching 36 weeks showed significant improvement in the six-minute walk test (+95.9 m) and in the symptom assessment scale. Extended follow-up reported a cumulative 6MWT improvement of 96.1 m at week 168 (p = 0.003) in the eight patients reaching that visit, with improvement in three-dimensional left ventricular volumes and in the MLCL/CL ratio (PMID 38602181).

The honest reading is that the randomised evidence is negative and the open-label evidence is positive, in a disease with fewer than 200 identified patients worldwide. Open-label extensions in ultra-rare disease are vulnerable to survivor selection, learning effects on walk tests and regression to the mean, and are also, sometimes, the only data obtainable.

What Remains Unknown

No receptor or saturable binding site has been identified and the surface-electrostatics model implies none exists, which leaves the field without a straightforward way to establish target engagement in vivo. The relationship between dose, membrane occupancy and effect size is correspondingly ill-defined, and pharmacokinetics are thinly described: tissue distribution, intracellular residence time and duration of membrane occupancy after a single parenteral dose are all poorly characterised in the public literature.

The translational gap between rodent ischaemia-reperfusion and human infarction remains unexplained. Infarct-size reduction in animals is among the most reproducible findings in cardioprotection research and among the least likely to survive a human trial; SS-31 joins a long list. Whether the failure lies in timing, dose, the presence of modern reperfusion therapy, or the model itself is unresolved.

Finally, no biomarker predicts response. The MLCL/CL ratio improved in Barth syndrome, but that is a disease-specific readout of the causal defect, not a general pharmacodynamic marker. Outside Barth syndrome there is no validated way to identify a model or a patient whose mitochondria are the kind SS-31 helps.

Comparison: SS-31, MOTS-c and NAD+ Precursors

Three approaches get grouped under “mitochondrial research compounds” and share almost no mechanism. Keeping them separate is a study-design requirement.

SS-31 is a structural intervention: it changes the physical state of a membrane. MOTS-c is a signalling intervention acting through AMPK and nuclear transcription. NAD+ precursors are a substrate-supply intervention. The endpoints that detect one are often blind to the others, cristae morphology and respiratory-chain assembly for the first, AMPK phosphorylation for the second, NAD+ pool size for the third. Catalogues list MOTS-C peptide and NAD+ peptide as separate research compounds for precisely that reason.

Handling and Reconstitution of Lyophilised SS-31

At four residues and roughly 640 Da, SS-31 sits at the small end of what is conventionally called a peptide, and it is more robust than a 30-mer. Three properties shape handling.

It is highly water-soluble. The 3+ charge and absence of a hydrophobic core mean aqueous diluent is appropriate with no organic co-solvent, and solubility is rarely limiting. Worth stating, because it distinguishes SS-31 from the small molecules sometimes shelved beside it, which frequently do require DMSO.

It has no disulphide bonds, no methionine and no tryptophan which removes the three commonest degradation routes in research peptides. The oxidation-prone site is the dimethyltyrosine; the labile bond is the C-terminal amide. Lyophilised material held cold and dry is comparatively stable, and the reconstituted solution is where degradation occurs.

It adsorbs to surfaces. A small, strongly cationic molecule binds readily to glass and to untreated polypropylene, and at the dilute concentrations used in membrane work this is a real and frequently unrecognised source of potency loss. Low-binding tubes are worth the effort.

Practical reconstitution follows the standard sequence. Allow the vial to reach room temperature before opening so condensation does not form on the cold cake. Disinfect the septum with 70% isopropyl alcohol and let it dry. Introduce the diluent slowly down the inner wall of the vial rather than jetting it onto the cake, since a stream striking the cake creates local shear and an air-liquid interface. Swirl or roll gently; never shake.

Where a vial will be entered repeatedly, a preserved monographed diluent is the conventional choice, and bacteriostatic water of the sort listed beside research compounds at NextGenPeps, or an equivalent Bacteriostatic Water for Injection, USP product, is what most laboratory protocols specify. Two caveats belong in the record. The benzyl alcohol preservative is not inert toward peptides, the formulation literature documents preservative-promoted unfolding and aggregation across multiple model peptides, so a single-entry analytical preparation is better served by unpreserved sterile water, which adds no destabilising excipient. And bacteriostatic water is contraindicated in neonatal use because of benzyl alcohol toxicity, a restriction that belongs in handling notes even where no clinical use is contemplated.

Store reconstituted solution at 2–8 °C for short-term work, protected from light, and aliquot at the point of reconstitution rather than freeze-thawing one vial repeatedly. Record the resulting concentration in mg/mL rather than the volume added, and log the diluent lot alongside the peptide lot so a stability question raised weeks later stays answerable from the record.

Is SS-31 FDA Approved?

This question needs a more careful answer for SS-31 than for almost any other compound in the research catalogue, and the careful answer is: a prescription product containing this molecule exists, and research-grade SS-31 is not it.

On 19 September 2025 the FDA granted accelerated approval to Forzinity (elamipretide) injection under NDA 215244, indicated to improve muscle strength in adult and paediatric patients with Barth syndrome weighing at least 30 kg (FDA approval letter). The approval rests on a surrogate endpoint improvement in knee extensor muscle strength by handheld dynamometry, and carries a post-marketing requirement for a randomised, double-blind, placebo-controlled confirmatory trial, with initiation scheduled for March 2026 and a final report due March 2030. Accelerated approval on a surrogate endpoint is a provisional regulatory judgement, not a settled one, and it can be withdrawn if the confirmatory trial fails.

The scope is narrow in every dimension that matters: one manufactured product one strength, one route, for one ultra-rare genetic disease defined by a specific defect in cardiolipin remodelling, above a weight threshold. Elamipretide has separately held orphan-drug and fast-track designations for Barth syndrome; its programmes in primary mitochondrial myopathy, heart failure and myocardial infarction produced negative primary endpoints and no approvals.

None of that confers any status on research-grade SS-31. A vial of lyophilised tetrapeptide sold to a laboratory is not an approved drug product: no marketing authorisation, no approved labelling, no regulated manufacturing standard, no established sterility or endotoxin specification, no approved route of administration. It is research-use-only material, and the existence of an approved product elsewhere makes the sourcing question sharper rather than softer, because it creates an obvious temptation to read approved-product framing onto unregulated material. Laboratories working in sport-science contexts should separately verify the current status of mitochondria-targeted peptides under the applicable prohibited list.

Where to Source Research-Grade SS-31

Because nothing regulatory underwrites laboratory material, the purchase record is the only evidence a laboratory has. A defensible one contains:

• A lot-matched certificate of analysis tied to the specific lot shipped rather than to a representative batch.
• Third-party HPLC purity data with a named laboratory and a test date. For a tetrapeptide with a non-standard residue the realistic impurities are incomplete dimethylation of the tyrosine, epimerisation at the arginine and deamidation at the C-terminal amide, none of which a low-resolution chromatogram resolves.
• Mass spectrometry confirming identity with an observed mass consistent with the expected ~640 Da free base. D-arginine cannot be distinguished from L-arginine by mass at all, which is why synthesis documentation matters alongside the analytical certificate.
• Declared net peptide content distinct from gross vial fill weight. For a compound this small the counterion fraction is proportionally large.
• Residual solvent and water content figures where available, because trifluoroacetate from purification affects both effective mass and downstream cell viability.
• Cold-chain shipping and light-protective packaging and explicit research-use-only labelling with no suggested protocol, dosing guidance or human-use framing anywhere in the listing.

Red flags are mostly absences and overreaches. A certificate with no laboratory name, test date or lot reference is decoration rather than evidence, and a supplier who will not produce documentation for the lot in hand has answered the question. Purity claims of “99%+” with no chromatogram, no method and no named laboratory are not data. A listing that supplies an injection schedule, a human protocol or a therapeutic claim has left the research-use-only frame entirely, and for this compound specifically, any listing that borrows the approved product’s indication, brand name or trial results to describe unregulated material should be read as a compliance failure rather than a marketing flourish. A catalogue that lists SS-31 peptide as a research compound can be assessed against exactly these criteria: lot-matched third-party analysis, confirmed identity by mass spectrometry, declared net peptide content, cold-chain handling, and research-use-only labelling with no protocol content attached.

Frequently Asked Questions

Is SS-31 the same thing as elamipretide?

The same molecule under different names. SS-31 is the laboratory designation from the Szeto–Schiller series; elamipretide is the international non-proprietary name used in clinical development; MTP-131 and Bendavia are earlier development codes. A research vial labelled SS-31 and a prescription product labelled elamipretide contain the same tetrapeptide but are not the same thing as products, one is unregulated research material, the other a manufactured drug with approved specifications.

Is SS-31 an antioxidant?

Not primarily, on the current mechanistic reading. The original 2004 characterisation used antioxidant language, and reduced reactive oxygen species is a consistently reported effect. But the mechanistic work points to cardiolipin association and modulation of membrane surface electrostatics as the proximate actions, with lower ROS following from a respiratory chain that leaks fewer electrons. A study using only a ROS endpoint cannot distinguish SS-31 from a generic scavenger.

Did the elamipretide clinical trials work?

The randomised trials largely did not. EMBRACE STEMI showed no reduction in infarct size by CK-MB area under the curve. PROGRESS-HF showed no change in left ventricular end-systolic volume or ejection fraction in heart failure. MMPOWER-3 did not improve the six-minute walk test or fatigue in primary mitochondrial myopathy. The randomised phase of TAZPOWER in Barth syndrome also missed both primary endpoints; its open-label extension reported large functional gains, and that open-label evidence underpinned an accelerated approval on a surrogate endpoint.

Why was Barth syndrome the indication that succeeded?

Because the mechanistic fit is exact. Barth syndrome results from TAZ mutations that disrupt cardiolipin remodelling, leaving an elevated ratio of monolysocardiolipin to mature cardiolipin. A cardiolipin-directed compound in a cardiolipin-remodelling disease is a far tighter hypothesis than the same compound in generic heart failure. That said, the approval rests on a surrogate strength endpoint in a very small population and carries a confirmatory-trial requirement.

What doses have been used in animal studies?

Rodent ischaemia-reperfusion work has typically used intravenous or intraperitoneal administration in the range of roughly 1–3 mg/kg, frequently as an infusion started shortly before reperfusion, with lower per-kilogram rates in large-animal models. In vitro work generally uses nanomolar to low-micromolar concentrations, with peptide-to-lipid ratio the more meaningful variable in membrane studies. These figures are reported as they appear in the cited preclinical literature and do not translate to other species, routes or contexts.

How does SS-31 differ from MOTS-c?

They share a stated target organelle and little else. SS-31 is a synthetic 640 Da tetrapeptide that associates with cardiolipin in the inner membrane and alters membrane surface electrostatics, a structural intervention. MOTS-c is an endogenous 16-residue peptide encoded within mitochondrial DNA that acts through AMPK and nuclear transcription, a signalling intervention. Their endpoints barely overlap.

The Bottom Line

SS-31 is the best-characterised mitochondria-targeted peptide in existence, and it is a cautionary tale about what characterisation buys you. Two decades of work have produced an unusually clear mechanistic account: a small aromatic polycation that adsorbs to the inner mitochondrial membrane independently of membrane potential, associates with cardiolipin, alters membrane surface electrostatics, preserves the cardiolipin–cytochrome c interaction, and thereby restores electron transport efficiency. That account is supported by biophysics, cross-linking proteomics and structure-activity work across the tetrapeptide series. Very few research compounds have anything comparable.

The preclinical record in cardiac and pulmonary models is broad and directionally consistent: smaller infarcts in ischaemia-reperfusion, improved ventricular and mitochondrial function in canine heart failure, attenuated pulmonary arterial hypertension and acute lung injury in rodents. For a cardiothoracic research programme this is a well-motivated compound with a clear hypothesis and measurable organelle-level endpoints.

And then the human trials. No infarct-size reduction in STEMI. No change in ventricular volumes in heart failure. No improvement in walk distance or fatigue in primary mitochondrial myopathy. One accelerated approval, on a surrogate endpoint, in an ultra-rare disease whose causal defect is cardiolipin remodelling itself, a genuine achievement, and also the narrowest possible confirmation of the mechanism, with the confirmatory trial still to report.

That pattern is the useful lesson. Mechanistic clarity at the level of a membrane phospholipid did not predict clinical benefit in the large indications, and the one indication where it did was the one where the mechanism and the disease were the same thing. Laboratories treating SS-31 as a tool for interrogating cardiolipin biology and cristae organisation are using it for what the evidence supports.

By [AUTHOR NAME PLACEHOLDER], [CREDENTIALS PLACEHOLDER]. Fact-checked by [FACT-CHECKER NAME PLACEHOLDER].

Research Use Only Disclaimer

SS-31 and all other compounds discussed in this article are intended for laboratory research use only. Research-grade SS-31 is not an approved drug product: no marketing authorisation, no approved labelling, no regulated manufacturing or sterility standard, no approved route of administration. The existence of an FDA-approved prescription product containing elamipretide for a single ultra-rare indication confers no regulatory status whatsoever on research-grade material.

Nothing here is medical, veterinary or pharmaceutical advice, and nothing in it constitutes a dosing recommendation, a protocol for use in humans or animals, or a therapeutic claim of any kind. Research peptides described here are not for human or veterinary use. Doses and concentrations quoted from the published literature are reported in the terms the original investigators used, milligrams per kilogram in the named animal model, or molar concentrations in the named cell or membrane system, and are not recommendations, conversions or equivalents for any other species or route. Descriptions of clinical trial results are summaries of the published scientific and regulatory record, not statements about what any compound does in any individual. Readers with clinical questions should consult a qualified healthcare professional. Bacteriostatic Water for Injection, USP contains benzyl alcohol and is contraindicated in neonates. Readers are responsible for compliance with all applicable laws, institutional review and animal ethics requirements, anti-doping regulations and biosafety rules in their jurisdiction.

Stay updated, free articles. Join our Telegram channel

Join